All In Biotech

Drug Trial Radar · NCT07049926

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Jul 20, 2025

Primary completion

Oct 26, 2031

Study completion Oct 26, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Exelixis
First posted
Jul 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with clear cell renal cell carcinoma (ccRCC) who have recurrent disease during or after anti-programmed cell death 1/programmed cell death ligand 1 (PD-\[L\]1) adjuvant therapy. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study

Conditions

  • Renal Cell Carcinoma

Interventions

  • BelzutifanDrug

    Oral Tablet

  • ZanzalintinibDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Lead In Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Up to approximately 21 days
  2. Safety Lead In Phase: Number of participants who experience one or more adverse events (AEs)Time frame: Up to approximately 74 months
  3. Safety Lead In Phase: Number of participants who discontinue study treatment due to an AETime frame: Up to approximately 74 months
  4. Efficacy Phase: Number of participants who experience one or more DLTsTime frame: Up to approximately 21 days
  5. Efficacy Phase: Number of participants who experience one or more AEsTime frame: Up to approximately 74 months
  6. Efficacy Phase: Number of participants who discontinue study treatment due to an AETime frame: Up to approximately 74 months
  7. Efficacy Phase: Objective Response Rate (ORR)Time frame: Up to approximately 74 months

Locations

33 sites in 8 countries. Site status is shown where the registry gives one.

  • UCSF Medical Center at Mission Bay ( Site 5008)

    San Francisco, California · Recruiting

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5026)

    Mineola, New York · Recruiting

  • Laura and Isaac Perlmutter Cancer Center ( Site 5016)

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center ( Site 5002)

    New York, New York · Recruiting

  • Duke Cancer Institute ( Site 5015)

    Durham, North Carolina · Recruiting

  • UPMC Cancer Center/Hillman Cancer Center ( Site 5017)

    Pittsburgh, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center ( Site 5004)

    Nashville, Tennessee · Recruiting

  • Centro de Estudios Clínicos SAGA ( Site 6110)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • CDIEM ( Site 6114)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill ( Site 6101)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • C.H.U. de Strasbourg Hopital de Hautepierre ( Site 5203)

    Strasbourg, Bas-Rhin, France · Recruiting

  • Institut Claudius Regaud ( Site 5200)

    Toulouse, Haute-Garonne, France · Recruiting

  • Gustave Roussy ( Site 5202)

    Villejuif, Île-de-France Region, France · Recruiting

  • Centre Eugene Marquis ( Site 5205)

    Rennes, Ille-et-Vilaine, France · Recruiting

  • Institut De Cancerologie De Lorraine ( Site 5204)

    Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France · Recruiting

  • Rambam Health Care Campus ( Site 5500)

    Haifa, Israel · Recruiting

  • Rabin Medical Center ( Site 5502)

    Petah Tikva, Israel · Recruiting

  • Sheba Medical Center ( Site 5501)

    Ramat Gan, Israel · Recruiting

  • Sourasky Medical Center ( Site 5503)

    Tel Aviv, Israel · Recruiting

  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 6201)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland · Recruiting

  • Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie ( Site 6203)

    Warsaw, Masovian Voivodeship, Poland · Recruiting

  • Uniwersyteckie Centrum Kliniczne ( Site 6202)

    Gdansk, Pomeranian Voivodeship, Poland · Recruiting

  • Severance Hospital ( Site 5802)

    Seoul, South Korea · Recruiting

  • Asan Medical Center ( Site 5800)

    Seoul, South Korea · Recruiting

  • Samsung Medical Center ( Site 5801)

    Seoul, South Korea · Recruiting

  • Hospital Universitari Vall d'Hebron ( Site 5300)

    Barcelona, Spain · Recruiting

  • HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 5302)

    Madrid, Madrid, Comunidad de, Spain · Recruiting

  • Hospital Universitario Ramon y Cajal ( Site 5301)

    Madrid, Madrid, Comunidad de, Spain · Recruiting

  • Velindre Cancer Centre ( Site 5407)

    Cardiff, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust ( Site 5400)

    Manchester, United Kingdom · Recruiting

  • Western General Hospital ( Site 5402)

    Edinburgh, Edinburgh, City of, United Kingdom · Recruiting

  • The Beatson West of Scotland Cancer Centre ( Site 5405)

    Glasgow, Glasgow City, United Kingdom · Recruiting

  • St Bartholomew's Hospital ( Site 5401)

    London, London, City of, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.